TY - JOUR
T1 - Sacituzumab for the treatment of triple-negative breast cancer
T2 - the poster child of future therapy?
AU - Zangardi, Mark L.
AU - Spring, Laura M.
AU - Nagayama, Aiko
AU - Bardia, Aditya
N1 - Funding Information:
A Bardia has disclosed consulting fees from Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma and Taiho Pharma, a research grant from Biothernostics and institutional funding from Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Sanofi and Mersana Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Funding Information:
This paper was funded by the National Cancer Institute (NCI) and the Susan G Komen Foundation. A Bardia received funding support from NCI grant K12 CA087723 and a Susan G Komen Foundation grant CCR15224703. L Spring has received funding support from NCI grant KL2 TR001100.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered: We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion: Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3 rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.
AB - Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered: We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion: Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3 rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.
KW - Antibody–drug conjugate
KW - IMMU-132
KW - TNBC
KW - metastatic breast cancer
KW - sacituzumab govitecan
KW - triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85058695280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058695280&partnerID=8YFLogxK
U2 - 10.1080/13543784.2019.1555239
DO - 10.1080/13543784.2019.1555239
M3 - Article
C2 - 30507322
AN - SCOPUS:85058695280
SN - 1354-3784
VL - 28
SP - 107
EP - 112
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 2
ER -
